CGON · Cg Oncology Inc
United States · RS rating 38 · As of 2026-10-14
| Price | 61.84 USD |
|---|---|
| 1-day change | -0.9% |
| RS rating (overall / 1M / 3M / 12M) | 38 / 16 / 30 / 88 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 41 / 42 / 8 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -26.8% |
| Sales growth Q/Q | +39.4% |
| Distance from 52-week high | +23.4% |
| Market cap (USD) | $5.9B |